Table 3.

TAPUR study cohorts that have been closed as of February 20, 2020^* (adapted).

Treatment	Cancer	Variant	Findings
Pertuzumab + Trastuzumab	Colorectal	ERBB2 amplification or overexpression	Positive
	Colorectal	ERBB2/ERBB3 mutation	Pending
Vemurafenib + Cobimetinib	Colorectal	BRAF V600E/D/K/R mutation	Positive
Pembrolizumab	Metastatic breast	High tumor mutational burden	Positive[25]
	Colorectal	High tumor mutational burden	Positive
Palbociclib	Non-small-cell lung	CDKN2A alterations	Positive[24]
	Pancreatic	CDKN2A loss or mutation	Negative
	Gallbladder and bile ducts	CDKN2A loss or mutation	Negative
Sunitinib	Colorectal	FLT-3 mutation or amplification	Negative
Cetuximab	Breast	KRAS, NRAS, BRAF wild type	Negative
	Bronchus and lung	KRAS, NRAS, BRAF wild type	Negative
	Ovarian	KRAS, NRAS, BRAF wild type	Pending
Olaparib	Colorectal	ATM mutation or deletion	Pending
	Prostate	BRCA1/BRCA2 mutation	Pending
	Pancreatic	BRCA1/BRCA2 mutation	Pending

^⁎Accessed on March 23, 2020.